Canada markets closed
  • S&P/TSX

    19,062.91
    +345.79 (+1.85%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.32 (+2.68%)
     
  • CAD/USD

    0.7759
    +0.0064 (+0.83%)
     
  • CRUDE OIL

    107.06
    +2.79 (+2.68%)
     
  • BTC-CAD

    27,414.09
    +12.18 (+0.04%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • GOLD FUTURES

    1,828.10
    -1.70 (-0.09%)
     
  • RUSSELL 2000

    1,765.74
    +54.06 (+3.16%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • NASDAQ

    11,607.62
    +375.43 (+3.34%)
     
  • VOLATILITY

    27.23
    -1.82 (-6.27%)
     
  • FTSE

    7,208.81
    +188.36 (+2.68%)
     
  • NIKKEI 225

    26,491.97
    +320.72 (+1.23%)
     
  • CAD/EUR

    0.7347
    +0.0040 (+0.55%)
     

Cipher Pharmaceuticals Schedules Q1 2022 Earnings Release and Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

OAKVILLE, ON, May 9, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q1 2022 financial results on Thursday, May 12, 2022 after market close. The Company will also host a conference call on Friday, May 13, 2022 at 8:30am ET to discuss the results and corporate developments.

CONFERENCE CALL DETAILS

DATE:

May 13, 2022

TIME:

8:30 a.m. ET

DIAL-IN NUMBER:

(647) 484-0477 or (888) 458-4121

CONFERENCE ID:

6137413

REPLAY DIAL-IN:

(888) 203-1112 (playback 6137413#)


Expires May 20, 2022

WEBCAST:

https://produceredition.webcasts.com/starthere.jsp?ei=1548662&tp_key=a2eab0e46f

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

SOURCE Cipher Pharmaceuticals Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/May2022/09/c9976.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting